top of page
Search
Lipid Nanoparticle (LNP) News Brief Summary (April 29 – May 12, 2025)
Mana.bio: Presented new data demonstrating AI-driven safety model for lipid nanoparticle tolerability to enhance RNA medicine.
Grit Biotechnology: Presented scientific breakthroughs at ASGCT 2025 including LNP-mediated CRISPR/Cas9 gene editing for enhancing tumor-infiltrating lymphocytes.
Generation Bio: Reported business highlights including advancement of their cell-targeted lipid nanoparticle (ctLNP) technology for siRNA delivery.
Aera Therapeutics: Shifted focus
1 day ago


High-Throughput Screening of Lipid Nanoparticles for Efficient CRISPR RNA Delivery In Vitro and in Vivo
Efficient and precise delivery of CRISPR/Cas9 components remains one of the critical challenges toward the advancement of gene-editing therapies. Here, we have developed a high-throughput Barcode-Integration Nanoparticle Screen (BINS) method to evaluate a library of 96 lipid nanoparticles (LNPs) for their delivery efficiency across in vitro and in vivo models.
2 days ago


PreciGenome at ASGCT 28th Annual Meeting May 13-17, 2025
Excited to announce that PreciGenome will be exhibiting at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans, May 13-17, 2025! Join us at Booth #1818 to discover our latest innovations in:
Lipid Nanoparticle (LNP) Synthesis Systems: Experience our NanoGenerator™ platform, designed for scalable, reproducible, and cost-effective LNP, liposome, and PLGA nanoparticle production-ideal for applications from early discovery to GMP manufact
May 5


April 21-28, 2025 Lipid Nanoparticle (LNP) News Brief Summary
StatNano/Grand View Research: A new market report forecasts the global lipid nanoparticle market to reach $1.54 billion by 2030, growing at a CAGR of 13.64%, driven by increased demand for innovative drug delivery solutions.
SyVento BioTech: SyVento BioTech participates in the World Vaccine Congress in Washington, D.C., showcasing their expertise in lipid-based nanocarriers and LNP technology for pharmaceutical products including RNA-based drug products.
Arbor Biotechno
Apr 28


Lipid Nanoparticle (LNP) News Summary (April 14–21, 2025)
Arbor Biotechnologies: Unveiled FDA approval of an IND filing for their LNP-mediated treatment for primary hyperoxaluria type 1.
Rothwell Figg (Dan Shores): Led a workshop on intellectual property challenges for LNP-based therapies at the LNP Summit.
NOF CORPORATION: Presented biodegradable LNPs with tunable immunogenicity for vaccine and gene therapy applications.
Serina Therapeutics: Introduced immune-silent POZ-lipid technology as a PEG alternative for LNPs at the
Apr 21


Lipid Nanoparticle (LNP) Drug Delivery Advances, April 7-14, 2025
University of Pennsylvania: Developed nitro-oleic acid-modified LNPs for safer plasmid DNA delivery, enabling long-term gene expression in mice.
ACS Biochemistry Study: Introduced click chemistry LNPs for targeted mRNA delivery to metabolically labeled cancer cells.
Marama Labs: Launched CloudSpec, a tool for rapid lipid nanoparticle analysis, reducing lab times from hours to seconds.
Global Market Report: Projected lipid nanoparticle market growth to US$2.39 billion by 20
Apr 14


bottom of page